In Timor-Leste and Fiji the study will build local capacity for health financing equity analysis within the MoH and collaborating universities by providing practical training in BIA and FIA. A user-friendly toolkit on how to analyse health financing equity will be developed for use by policymakers and development partners in the region. The results will be disseminated through further info stakeholder meetings, targeted multidisciplinary workshops, seminars, journal publications, policy briefs, podcasts and the use of other electronic and web-based technologies

appropriate to the audiences to maximise awareness and utilisation of the findings. Supplementary Material Reviewer comments: Click here to view.(5.2K, pdf) Footnotes Contributors: ADA contributed to the design of this study and drafted the manuscript. JP contributed to the drafting of the manuscript. AH contributed

to the design of the study and reviewed the manuscript. WI and JM provided the local contents for Fiji and Timor-Leste. LG, JEA, AM and SJ contributed to the design of the study and reviewed the manuscript. VW conceived and designed the study, and oversaw the preparation of the manuscript. All authors read and approved the final manuscript. Funding: Funding for this study is provided by the Australian Aid through the Australian Development Research Awards (ADRAs) scheme. Competing interests: None. Ethics approval: The study is approved by the Human Research Ethics Committee of University of New South Wales, Australia (Approval number: HC13269); the Fiji National Health Research Committee (Approval # 201371); and the Timor-Leste Ministry of Health (Ref MS/UNSW/VI/218). Provenance and peer review: Not commissioned; peer reviewed for ethical and funding approval prior to submission. Data sharing statement: No additional data are available.
The term ‘aspirin resistance’ has been used to describe the

failure of aspirin to produce an expected response on one or more laboratory measures of platelet activation and aggregation.1 Mechanistic approaches to investigating aspirin resistance have relied mostly on ex vivo evaluations Dacomitinib of platelet function.2 However, while platelet aggregability is a major contributor to occlusive vascular events,3 other factors, such as vascular endothelial dysfunction,4 clotting protein cascades5 and flow stasis6 are also relevant. This multifactorial complexity, along with differing methods for making ex vivo assessments of platelet function, have made linkage between abnormal platelet function on laboratory indices and hard clinical events inconsistent. As a result, defining ‘aspirin resistance’ primarily based on currently available laboratory measures may not necessarily be the most appropriate way of discriminating people at high risk for future vascular events while on aspirin.